BMY

⚡ 1-Minute Take

Data sources: market data, fundamentals, news providers. Data may be delayed.

Key Statistics

MoonshotScore Breakdown: 58.0/100

📰 Latest News

Bristol-Myers Squibb pioneers innovative biopharmaceutical solutions, leveraging a diverse portfolio of oncology, hematology, and immunology drugs, including Eliquis and Opdivo, to address unmet medical needs and deliver strong shareholder value with a 4.02% dividend yield and a 14.6% profit margin.

About BMY

Bristol-Myers Squibb (BMY) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for serious diseases. With a diverse portfolio spanning oncology, hematology, immunology, and cardiovascular diseases, BMY aims to transform patients' lives through science.

Bristol-Myers Squibb Company Company Overview

Founded in 1887, Bristol-Myers Squibb (BMY) has evolved into a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for patients with serious diseases. Originally known as Bristol-Myers Company, the company has a rich history of scientific innovation and a commitment to addressing unmet medical needs. BMY's diverse portfolio includes market-leading products across several therapeutic areas, including oncology, hematology, immunology, cardiovascular, and fibrotic diseases. Key products include Revlimid, an oral immunomodulatory drug for multiple myeloma; Eliquis, an oral inhibitor for stroke prevention and treatment of DVT/PE; and Opdivo, an anti-cancer therapy for various indications. Other notable products include Pomalyst/Imnovid, Orencia, Sprycel, Yervoy, Abraxane, Reblozyl, Empliciti, Zeposia, Breyanzi, Inrebic, and Onureg. BMY markets its products globally through wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies, maintaining a strong presence in key markets worldwide. With a workforce of 34,100 employees, BMY continues to invest in research and development to drive future growth and deliver innovative therapies to patients in need.

Investment Thesis

Bristol-Myers Squibb presents a compelling investment opportunity driven by its diverse portfolio of established and innovative biopharmaceutical products. With a market capitalization of $126.20 billion and a P/E ratio of 17.89, BMY offers a blend of value and growth potential. The company's strong profit margin of 14.6% and gross margin of 63.1% demonstrate its ability to generate significant earnings. Key growth catalysts include the continued expansion of Opdivo and Eliquis, as well as the successful launch of new products like Zeposia and Breyanzi. BMY's commitment to research and development, coupled with strategic acquisitions and partnerships, positions it for long-term growth and value creation. The company's attractive dividend yield of 4.02% provides investors with a steady stream of income while benefiting from potential capital appreciation.

Key Financial Highlights

• Market capitalization of $126.20 billion reflects BMY's significant presence in the biopharmaceutical industry.
• P/E ratio of 17.89 indicates a reasonable valuation relative to earnings.
• Profit margin of 14.6% demonstrates strong profitability and operational efficiency.
• Gross margin of 63.1% highlights BMY's ability to maintain competitive pricing and manage costs effectively.
• Dividend yield of 4.02% provides an attractive income stream for investors.

Industry Context

Bristol-Myers Squibb operates in the highly competitive drug manufacturing industry, characterized by intense research and development, stringent regulatory requirements, and patent protection. The global pharmaceutical market is expected to continue growing, driven by an aging population, increasing prevalence of chronic diseases, and advancements in medical technology. BMY competes with other major pharmaceutical companies, such as GSK, CI, CVS, and ELV, for market share and innovation leadership. The company's success depends on its ability to develop and commercialize innovative therapies, navigate regulatory hurdles, and maintain a strong competitive position in key therapeutic areas.

Quarterly Financial Summary

Source: Company filings. Data may be delayed.

Growth Opportunities

• Expansion of Opdivo into new indications: Opdivo, BMY's leading anti-cancer therapy, has the potential for further growth through expansion into new indications and combination therapies. The global oncology market is projected to reach $350 billion by 2030, providing a significant opportunity for BMY to increase Opdivo's market share and drive revenue growth. This expansion is ongoing as of 2026-02-09.
• Growth of Eliquis in the cardiovascular market: Eliquis, an oral inhibitor for stroke prevention and treatment of DVT/PE, continues to experience strong growth in the cardiovascular market. With the increasing prevalence of atrial fibrillation and venous thromboembolism, Eliquis is well-positioned to capture a larger share of the market, which is expected to reach $30 billion by 2028. This growth is ongoing as of 2026-02-09.
• Successful launch of new products: BMY's recent launches of Zeposia for multiple sclerosis and Breyanzi for lymphoma represent significant growth opportunities. These innovative therapies address unmet medical needs and have the potential to generate substantial revenue. The market for multiple sclerosis therapies is expected to reach $25 billion by 2027, while the market for lymphoma therapies is projected to reach $20 billion by 2028. This launch is ongoing as of 2026-02-09.
• Strategic acquisitions and partnerships: BMY has a history of strategic acquisitions and partnerships to expand its pipeline and strengthen its market position. These collaborations provide access to new technologies, therapeutic areas, and markets, driving long-term growth and innovation. BMY will continue to explore strategic opportunities to enhance its portfolio and create value for shareholders. This strategy is ongoing as of 2026-02-09.
• Emerging Markets Expansion: Expanding into emerging markets presents a significant growth opportunity for BMY. These markets, characterized by rapidly growing populations and increasing healthcare spending, offer substantial potential for increased sales and market share. BMY can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets and drive revenue growth. This expansion is ongoing as of 2026-02-09.

Competitive Advantages

• Strong intellectual property protection through patents and exclusivity.
• Established brand reputation and trust among healthcare professionals.
• Extensive research and development capabilities.
• Global distribution network and market access.

Strengths

• Diverse portfolio of established and innovative products.
• Strong research and development capabilities.
• Global presence and distribution network.
• Experienced management team.

Weaknesses

• Reliance on key products with patent expirations.
• Exposure to generic competition.
• High research and development costs.
• Regulatory and legal risks.

Opportunities

• Expansion into new therapeutic areas.
• Strategic acquisitions and partnerships.
• Growth in emerging markets.
• Development of personalized medicine.

Threats

• Increasing competition from generic and biosimilar drugs.
• Pricing pressures and healthcare reforms.
• Unfavorable clinical trial results.
• Product liability claims.

What BMY Does

• Discovers and develops innovative biopharmaceutical products.
• Licenses and manufactures pharmaceutical products.
• Markets and sells biopharmaceutical products globally.
• Offers therapies for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and COVID-19 diseases.
• Provides treatments for multiple myeloma, stroke prevention, and various cancers.
• Sells products to wholesalers, distributors, pharmacies, hospitals, and government agencies.

Business Model

• Develops and patents innovative pharmaceutical products.
• Manufactures and distributes drugs through various channels.
• Generates revenue through the sale of prescription medications.
• Invests heavily in research and development to discover new therapies.

Key Customers

• Wholesalers and distributors of pharmaceutical products.
• Pharmacies and retailers that dispense medications.
• Hospitals and clinics that administer treatments.
• Government agencies and healthcare providers.

Competitors

• Cigna (CI): Diversified healthcare services company.
• CVS Health (CVS): Pharmacy and healthcare services provider.
• Elevance Health (ELV): Health insurance and healthcare services company.
• GSK plc (GSK): Global pharmaceutical company.
• HCA Healthcare (HCA): Hospital and healthcare facilities operator.

Catalysts

• Upcoming: Clinical trial results for new drug candidates in oncology and immunology.
• Ongoing: Expansion of Opdivo into new indications and combination therapies.
• Ongoing: Successful launch and market penetration of Zeposia and Breyanzi.
• Ongoing: Strategic acquisitions and partnerships to expand the pipeline.

Risks

• Potential: Patent expirations on key products leading to generic competition.
• Potential: Unfavorable clinical trial results impacting drug development.
• Ongoing: Regulatory and legal challenges related to drug pricing and marketing.
• Ongoing: Competition from other pharmaceutical companies and biosimilar manufacturers.

FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Related Stocks in Drug Manufacturers - General

Browse More

Next Steps